Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is a clinical-stage pharmaceutical company with a promising drug candidate, Stenoparib, for advanced ovarian cancer and a unique Drug Response Predictor technology that improves patient selection. While there are long-term development challenges and high risks, recent Q4 results showed revenue of $0.3 million and a net loss of $3.4 million, slightly better than analyst estimates. Given its potential for growth and promising fundamentals, the stock may be a high-risk, high-reward opportunity for investors.

Bears say

Allarity Therapeutics is a clinical-stage biopharmaceutical company with a focus on developing anti-cancer therapeutics using precision medicine. However, the risks associated with the development of its lead drug, Stenoparib, including potential safety and efficacy concerns, delays in regulatory approvals, and competition in the market, outweigh the potential prospects and current valuation of the company. Additionally, the company's balance sheet and liquidity pose potential risks to the attainment of its share price target.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.